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Coronary Disease
Both Troponin and BNP Identify
Patients Who Benefit From Revascularization
Several studies have found that elevated levels of troponin identify acute coronarysyndrome patients at increased risk, and that these patients do better if revascular-
ized than if medically treated. James and colleagues confirm and expand these findings
with data from the GUSTO-IV trial. In this trial both troponin-T and N-terminal
pro-B-type natriuretic peptide (BNP) stratified patients as either high or low risk for
1-year mortality. Furthermore, subjects with elevated levels of either marker (for
troponin0.1 and237 ng/l for BNP) had lower mortality if they were revascular-
ized than those who were not revascularized. This study demonstrates that both
troponin and BNP cannot only identify those at increased risk of death, but can also
identify those most likely to benefit from revascularization. See page 1146.
Risk for
Cardiovascular Disease
Changes in the Risk Factors for CHD Among U.S. Adults
Recent studies have suggested that the risk of dying from coronary heart disease hasdecreased, but the reasons are unclear. Ajani and Ford compared data from the
National Health and Nutrition Examination Survey (NHANES) surveys in 1988 to
1994 and1999 to2002, todetermine if the 10-year Framinghamrisk of coronaryheart
disease (CHD) had changed.Overall, there was no difference in the risk of CHDor in
the percentages of respondents at high and intermediate risk; however, there were
changes in the individual risk factors. Specifically, the rates of smoking were less, but
therewas increased prevalence of diabetes and systolic hypertension that appeared to be
due to increased rates of obesity. This study suggests that overall risk has not changed
significantly and programs to reduce the risk of CHD need to be multi-pronged.
See page 1177.
Enhanced
External Counterpulsation
EECP Improves Functional Capacity in Patients With Systolic Dysfunction
Because of its transient ventricular unloading and improvements in peripheralvascular resistance, enhanced external counterpulsation (EECP)maybe beneficial
in patientswith systolic dysfunction.ThePEECH(Prospective Evaluation of EECP in
CongestiveHeart Failure) trial randomized subjectswith an ejection fraction35%to
either continued medical therapy or medical therapy plus 35 1-h EECP sessions.
Enhanced external counterpulsation resulted inmore subjects improving their exercise
treadmill time, but there were no improvements in oxygen utilization. The improve-
ment in functional capacity and heart failure symptoms suggests a role for EECP in
these patients, but the lack of change in other criteria raises questions about the placebo
effect. See page 1198.
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Heart Failure
Intravenous Iron Improves Heart Failure Symptoms
Anemia is common in patients with chronic heart failure (CHF) and is associatedwith higher morbidity andmortality. The combination of erythropoietin (EPO)
and iron increases hemoglobin (Hb) and improves symptoms and exercise capacity in
anemic CHF patients, but the efficacy of iron without EPO is unknown. Bolger and
colleagues performed a small pilot study in 16 patients withCHF andHb12mg/dl.
Subjects received up to five 10-ml infusions of 200mg of iron sucrose, which was well
tolerated. This resulted in an increase in mean Hb from 11.2 to 12.6 mg/dl and an
average 40-m improvement in the 6-min walk test and improvements in the Minne-
sota Living with Heart Failure score. This pilot study suggests the need for a larger,
randomized study of the efficacy of iron infusions in patients with anemia and CHF.
See page 1225. See figure.
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Heart Rhythm Disorders
Statins Reduce Mortality in Nonischemic Cardiomyopathies
Whereas the benefit of statins in patients with coronary artery disease isclear, their role in patients with nonischemic cardiomyopathies is less
clear. The DEFINITE trial studied patients with nonischemic cardiomyopa-
thies. Goldberger and colleagues reanalyzed the data and stratified subjects
based on whether or not they were taking statin medications. Despite similar
baseline characteristics, the rates of both total mortality and sudden arrhythmic
death were 5 times higher in those not taking statins. This study strongly
suggests that statins may improve mortality in patients with nonischemic
cardiomyopathies. See page 1228. See figure.
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Pediatric Cardiology
Impaired Heart Rate Response Predicts
Mortality in Adults With Congenital Heart Disease
There is a need for a simple test that can identify patients with a history ofcongenital heart disease (CHD) at increased risk for death. Diller and colleagues
examined the heart rate response to treadmill exercise and peak oxygen consumption
(peak VO2) in over 700 adults with CHD. An abnormal heart rate response to exercise
identified patients with an increased risk of mortality, independently of anti-
arrhythmic therapy, peak VO2, or functional class. Heart rate reserve, the difference
between peak heart rate and resting heart rate, is a simple and inexpensive way to
identify CHD patients at the greatest risk for death. See page 1250. See figure.
